A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study

Blood

Volumn 99, Issue 6, 2002, Pages 1986-1994

  Avramis, Vassilios I ^{a,b,c,d,e,f,g,h,i,j}   Sencer, Susan ^{a,b,c,d,e,f,g,h,i,j}   Periclou, Antonia P ^{a,b,c,d,e,f,g,h,i,j}   Sather, Harland ^{a,b,c,d,e,f,g,h,i,j}   Bostrom, Bruce C ^{a,b,c,d,e,f,g,h,i,j}   Cohen, Lewis J ^{a,b,c,d,e,f,g,h,i,j}   Ettinger, Alice G ^{a,b,c,d,e,f,g,h,i,j}   Ettinger, Lawrence J ^{a,b,c,d,e,f,g,h,i,j}   Franklin, Janet ^{a,b,c,d,e,f,g,h,i,j}   Gaynon, Paul S ^{a,b,c,d,e,f,g,h,i,j}   Hilden, Joanne M ^{a,b,c,d,e,f,g,h,i,j}   Lange, Beverly ^{a,b,c,d,e,f,g,h,i,j}   Majlessipour, Fataneh ^{a,b,c,d,e,f,g,h,i,j}   Mathew, Pracad ^{a,b,c,d,e,f,g,h,i,j}   Needle, Michael ^{a,b,c,d,e,f,g,h,i,j}   Neglia, Joseph ^{a,b,c,d,e,f,g,h,i,j}   Reaman, Gregory ^{a,b,c,d,e,f,g,h,i,j}   Holcenberg, John S ^{a,b,c,d,e,f,g,h,i,j}  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d SANOFI   (France)

^e SAINT PETER S UNIVERSITY HOSPITAL   (United States)

^f CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA   (United States)

^g UNIVERSITY OF NEW MEXICO   (United States)

^h CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

ⁱ CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^j SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AMINO ACID ANALYSIS; ANTIBODY TITER; AREA UNDER THE CURVE; ARTICLE; BONE MARROW BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CLEARANCE; DRUG SAFETY; ENZYME ACTIVITY; ENZYME METABOLISM; ESCHERICHIA COLI; FEMALE; HEMIPARESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITALIZATION; HUMAN; IMMUNOPHENOTYPING; INFECTION; LYMPHOBLAST; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; PHARMACODYNAMICS; PRIORITY JOURNAL; SEIZURE; SURVIVAL RATE; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 0037085747     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.6.1986     Document Type: Article

References (36)

1. Childhood leukemia
2. Factors which may influence the effectiveness of L-asparaginases as tumor inhibitors
3. Enzymes as drugs
4. Asparaginase
5. Toxicity of E coli asparaginase in man
6. Antibody response to Escherichia coli L-asparaginase: Prognostic significance and clinical utility of antibody measurement
7. Modified pharmacokinetics of L-asparaginase from E. coli by formation of specific antibodies to L-asparaginase of different immunoglobulin classes in children with acute lymphocytic leukemia
8. Immunological responses to L-asparaginase
9. Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia
10. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia
11. Pharmacology of Escherichia coli L-asparaginase polyethylene glycol adduct
12. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates
13. Comparative pharmacokinetic studies of three asparaginase preparations
14. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia
15. L-asparaginase and PEG asparaginase-past, present, and future
16. Clinical pharmacology of polyethylene glycol-L-asparaginase
17. Toxicity profile of PEG-L-asparaginase in native-L-asparaginase hypersensitive and non-hypersensitive patients with acute lymphoblastic leukemia
18. Antibodies to asparaginase alter pharmacokinetics and decrease enzyme activity in patients on asparaginase therapy [abstract]
19. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: A Pediatric Oncology Group study
20. Randomized trial of PEG- vs native-asparaginase in children with newly diagnosed acute lymphoblastic leukemia: CCG 1962
21. Population pharmacokinetics and pharmacodynamics of PEG-asparaginase in pediatric patients with acute lymphoblastic leukemia: CCG 1962
22. Sensitive analysis of asparagine and glutamine in physiological fluids and cells by precolumn derivatization with phenylisothiocyanate and reversed-phase high-performance liquid chromatography
23. Preclinical pharmacology and drug synergism studies of PEG-aspara-ginase (PEG-ASNase) and cytarabine (ara-C) in leukemia cell lines (CEM/0 and CEM/ara-C-7A)
24. Nonparametric estimation from incomplete observations
25. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
26. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: A report from the Children's Cancer Group
27. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia
28. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: A Children's Cancer Group phase III trial
29. Pegylated asparaginase (Oncaspar) in children with ALL: Drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols
30. Determination of anti-asparaginase antibody in pediatric patients in a high risk ALL study (CCG 1961): Correlation of AB and clinical allergy
31. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations
32. Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia
33. Measurement of serum L-asparagine in the presence of L-asparaginase requires the presence of an L-asparaginase inhibitor
34. A pharmacoeconomic analysis of pegaspargase vs native E. coli L-asparaginase for the treatment of children with standard risk acute lymphocytic leukemia CCG-1962